Soru

Zorluk: ZorHematology and Oncology

A 41-year-old woman is brought to the emergency department by her husband due to a 4-day history of profound fatigue, easy bruising, and recurrent nosebleeds. She has no significant past medical history and takes no medications. Vital signs show a temperature of 37.6∘C37.6^\circ \text{C} (99.7∘F99.7^\circ \text{F}), pulse of 110110/min, respirations of 1818/min, and blood pressure of 105/65105/65 mm Hg. Physical examination reveals pale mucous membranes, diffuse petechiae over the trunk and extremities, and continuous oozing of blood from a peripheral intravenous catheter site.

Laboratory studies reveal the following:

* Hemoglobin: 7.67.6 g/dL
* Leukocyte count: 3,200/μL3,200/\mu\text{L}
* Platelet count: 18,000/μL18,000/\mu\text{L}
* Prothrombin time: 2222 seconds
* Activated partial thromboplastin time: 4848 seconds
* Fibrinogen: 8080 mg/dL (Normal: 200200–400400 mg/dL)
* D-dimer: 8,5008,500 ng/mL (Normal: <500< 500 ng/mL)

Peripheral blood smear demonstrates large mononuclear cells with bilobed nuclei and abundant azurophilic granules; several of these cells contain multiple, needle-like eosinophilic inclusion bodies.

Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Bone marrow aspiration and biopsy
  2. B
    Initiation of cytarabine and daunorubicin therapy
  3. C
    Administration of high-dose intravenous dexamethasone
  4. Administration of all-trans retinoic acidCevap
  5. E
    Initiation of continuous unfractionated heparin infusion

Cevap

Administration of all-trans retinoic acid
This patient's clinical presentation is highly characteristic of acute promyelocytic leukemia (APL) complicated by disseminated intravascular coagulation (DIC). The peripheral smear describes atypical promyelocytes containing multiple Auer rods, which are pathognomonic for APL. APL is unique among leukemias because it frequently presents with a severe, life-threatening coagulopathy (elevated PT/aPTT, low fibrinogen, elevated D-dimer). The most critical initial step in management is the immediate administration of all-trans retinoic acid (ATRA). ATRA overcomes the differentiation block caused by the PML-RARA fusion protein, allowing the neoplastic promyelocytes to mature into functional neutrophils. This rapidly resolves the coagulopathy and dramatically reduces the risk of fatal hemorrhagic complications, such as intracranial hemorrhage. Because early mortality is so high, ATRA must be started upon clinical suspicion alone, prior to genetic or bone marrow confirmation.

Adım Adım Çözüm

1
Analyze the patient's presentation and laboratory findings.
The patient has severe bleeding, pancytopenia, and a coagulation profile consistent with disseminated intravascular coagulation (DIC): prolonged PT/aPTT, low fibrinogen, and markedly elevated D-dimer.
Identifying DIC is critical as it indicates a life-threatening, systemic consumptive coagulopathy.
2
Interpret the peripheral blood smear results.
The presence of large mononuclear cells with bilobed nuclei and multiple needle-like eosinophilic inclusion bodies (Auer rods) indicates acute promyelocytic leukemia (APL).
Auer rods are specific for myeloblasts and promyelocytes; multiple Auer rods ('faggot cells') are pathognomonic for APL.
3
Determine the pathogenesis of the coagulopathy.
The abnormal promyelocytes contain azurophilic granules that, when released, activate the coagulation cascade leading to severe DIC.
Understanding the mechanism dictates why standard cytolytic chemotherapy would be acutely dangerous.
4
Prioritize interventions.
Select immediate administration of all-trans retinoic acid (ATRA) over obtaining a definitive bone marrow biopsy.
Because APL-associated DIC carries an exceptionally high risk of early hemorrhagic death (e.g., intracranial hemorrhage), targeted treatment (ATRA) must begin based on clinical and peripheral smear suspicion alone, without waiting for cytogenetic confirmation.

Anahtar Kavram

In patients with suspected acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) must be administered immediately—prior to bone marrow biopsy confirmation—to rapidly reverse the life-threatening coagulopathy of disseminated intravascular coagulation (DIC).
Tahmini Süre:1m 30s
Bu soruyu puanla